Naaladase inhibitors

Claim 1

A pharmaceutical composition which comprises: i) an effective amount of a compound having the formula: ##STR8## where R is a C 1 -C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, phenyl, 1-napthyl, 2-napthyl, and phenyl (C 1 -C 4 alkyl), wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, 1-napthyl, 2-napthyl, or phenyl (C 1 -C 4 alkyl) groups are optionally substituted with a substituent selected from the group consisting of: C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, hydroxy, halo, hydroxyl, nitro, trifluoromethyl, C 1 -C 6 straight or branched chain alkyl or alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, phenoxy, benzyloxy, amino, and Ar 1 , where Ar 1 is selected from the group consisting of 1-napthyl, 2-napthyl, and phenyl, and where Ar 1 has one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 1 -C 4 alkoxy or C 2 -C 4 alkenyloxy, phenoxy, benzyloxy, and amino; or a pharmaceutically acceptable salt, hydrate or mixture thereof; ii) an effective amount of an additional therapeutic agent selected from the group consisting of therapeutic hormones, chemotherapeutic agents, monoclonal antibodies, anti-angiogenisis agents, radiolabelled compounds, and a mixture thereof; and (iii) a suitable pharmaceutical carrier.